Tau Vaccines

Tau Vaccines

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Vaccines</th>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">Tau pathology vaccine</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Multi-epitope vaccines</td>
<td>Academic consortia</td>
</tr>
<tr>
<td class="label">DNA vaccines</td>
<td>Biotech companies</td>
</tr>
<tr>
<td class="label">VLPs (Virus-like particles)</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Active Vaccines</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous/Intramuscular</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>Series (1-3 doses), then boosters</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Years of protection</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Patient-dependent</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Autoimmunity risk</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Active Vaccines</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower ($1K-5K/year)</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>Initial series + boosters</td>
</tr>
<tr>
<td class="label">Antibody Duration</td>
<td>Years (wit

Tau Vaccines

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Vaccines</th>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">Tau pathology vaccine</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Multi-epitope vaccines</td>
<td>Academic consortia</td>
</tr>
<tr>
<td class="label">DNA vaccines</td>
<td>Biotech companies</td>
</tr>
<tr>
<td class="label">VLPs (Virus-like particles)</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Active Vaccines</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous/Intramuscular</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>Series (1-3 doses), then boosters</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Years of protection</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Patient-dependent</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Autoimmunity risk</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Active Vaccines</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower ($1K-5K/year)</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>Initial series + boosters</td>
</tr>
<tr>
<td class="label">Antibody Duration</td>
<td>Years (with boosters)</td>
</tr>
<tr>
<td class="label">Antibody Quality</td>
<td>Variable (patient-dependent)</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Autoimmunity risk</td>
</tr>
<tr>
<td class="label">Patient Response</td>
<td>30-40% non-responders</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Location</td>
</tr>
<tr>
<td class="label">AADvac1</td>
<td>Europe/US</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Global</td>
</tr>
<tr>
<td class="label">Research consortia</td>
<td>Japan/EU</td>
</tr>
</table>

Active immunization (vaccines) against tau represent an innovative approach to treating Alzheimer's disease and related tauopathies. Unlike passive immunotherapy (monoclonal antibodies), active vaccines stimulate the patient's own immune system to produce anti-tau antibodies. This approach offers potential advantages including:

• Long-lasting Immunity: Single vaccination series may provide years of protection
• Lower Cost: Manufacturing and administration costs may be lower than biologics
• Broad Antibody Response: Multiple antibody specificities may be generated
• Patient Convenience: Fewer clinic visits required

• Age-Related Immune Decline: Elderly patients may have reduced vaccine response
• T cell Epitope Issues: Need to avoid triggering harmful autoimmune responses
• Antibody Affinity: Generated antibodies may have lower affinity than therapeutic mAbs

Tau Vaccine Mechanisms

Tau vaccines work by stimulating the immune system to produce antibodies that:

Tau Vaccine Programs in Development

AADvac1 (Axon Neuroscience)

AADvac1 is a tau vaccine developed by Axon Neuroscience that targets pathological tau proteins. It uses a synthetic peptide corresponding to amino acids 294-305 of the tau protein, which is a pathological epitope involved in tau aggregation[@aadvac2022][@tau2024].

• Developer: Axon Neuroscience (acquired by Liqun Biotechnology)
• Phase: Phase II completed
• Mechanism: Antibodies against pathological tau epitopes
• Target: Pathological tau conformations
• Key Results:
• Demonstrated safety and tolerability
• Generated anti-tau antibodies in majority of patients
• Slowed cognitive decline in biomarker-positive subgroup
• Phase II trial (NCT02542956) completed

ACI-35 (AC Immune / Janssen)

ACI-35 is a liposome-based tau vaccine that targets phosphorylated tau. It uses a liposomal delivery system to present phosphorylated tau peptides to the immune system, generating antibodies specific to pathologically phosphorylated tau[@tau2024][@aci].

• Developer: AC Immune / Janssen
• Phase: Phase Ib/IIa
• Mechanism: Anti-p-tau antibodies targeting phosphorylated epitopes
• Target: Phosphorylated tau at multiple pathological sites
• Clinical Trial: NCT04445831
• Key Results:
• Demonstrated robust antibody response
• Target engagement confirmed
• Good safety profile

Other Vaccine Approaches

Several other tau vaccine programs are in various stages of development:

Comparison to Passive Immunotherapy

Clinical Trial Considerations

Biomarker Endpoints

Tau vaccine trials utilize specific biomarker strategies:

Challenges in Vaccine Development

Advantages of Tau Vaccines

Limitations and Risks

Future Directions

The tau vaccine field continues to evolve with several promising directions:

Cross-Links to Related Pages

• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Passive Tau Immunotherapy](/therapeutics/anti-tau-immunotherapies)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [AADvac1](/therapeutics/aadvac1)
• [ACI-35 Liposomal Vaccine](/therapeutics/aci-35-liposomal-vaccine)

Detailed Clinical Trial Results

AADvac1 Phase II ADAMANT Trial

The ADAMANT trial (NCT02579252) was a randomized, double-blind, placebo-controlled Phase II study evaluating AADvac1 in patients with mild-to-moderate Alzheimer's disease[@aadvac2023].

Study Design:

• 196 patients randomized (1:1 to AADvac1 or placebo)
• 24-month treatment period
• Primary endpoint: Change in ADAS-Cog14
• Secondary endpoints: CSF biomarkers, tau PET

• Primary endpoint not met — no significant difference in cognitive decline
• Robust antibody response in 91% of treated patients
• Significant reduction in neurofilament light chain (NfL) in biomarker-positive subgroup
• Post-hoc analysis suggested benefit in patients with confirmed tau pathology
• Excellent safety profile — no ARIA (amyloid-related imaging abnormalities)

• 86% of patients developed anti-tau antibodies
• Reduced CSF total tau and p-tau181 in antibody responders
• Lower plasma NfL levels in treatment arm

• Population may have been too advanced (MCI to moderate AD)
• Antibody response alone may not be sufficient without sufficient brain penetration
• Patient selection based on tau pathology biomarkers may improve outcomes

ACI-35 Phase Ib/IIa Results

ACI-35 is a liposome-based vaccine targeting phosphorylated tau at Ser396/404, developed by AC Immune in collaboration with Janssen[@aci].

Phase Ib Results:

• Strong IgG antibody response in all participants
• Antibodies showed high specificity for phosphorylated tau
• No safety concerns observed
• Target engagement confirmed via CSF biomarkers

• Enrollment of patients with early AD
• Primary endpoint: Immune response at 12 months
• Secondary: Cognitive measures, CSF tau biomarkers

PSP and 4R-Tauopathy Focus

Tau vaccines are also being developed for primary tauopathies where 4R tau predominates:

AADvac1 in PSP:

• Separate Phase II trial in PSP patients
• Rationale: 4R tauopathies may respond better to immunotherapy
• Results: Generated antibodies but no clinical benefit in primary analysis
• Further analysis ongoing

Novel Vaccine Technologies

Liposome-Based Platforms

ACI-35 uses a liposomal delivery system that offers advantages:

• Co-delivery with adjuvant: Liposomes can contain both antigen and adjuvant
• Targeted delivery: Enhanced uptake by antigen-presenting cells
• Safety: Reduced risk of autoimmune reactions vs. complete Freund's adjuvant
• Flexibility: Easy to incorporate different tau epitopes

Virus-like Particles (VLPs)

VLPs represent an emerging approach:

• Non-replicating: Safe viral capsids without genetic material
• Multivalent display: Multiple tau epitopes per particle
• Strong immune response: VLP scaffolds enhance immunogenicity
• Research stage: Several academic programs in preclinical development

DNA Vaccines

DNA-based tau vaccines are in early development:

• Delivery: Plasmid DNA encoding tau epitopes
• In vivo production: Host cells produce the antigen
• Advantages: Repeatable dosing, no protein manufacturing
• Challenges: Optimal delivery method for CNS targeting

Multi-Epitope Strategies

Next-generation vaccines combine multiple tau targets:

• Rationale: Different disease stages involve different epitopes
• Approach: Combine N-terminal, mid-domain, and C-terminal epitopes
• Goal: Broader antibody response covering multiple tau species
• Status: Preclinical

Immune Response Optimization

Adjuvant Selection

The choice of adjuvant critically affects vaccine efficacy:

Alum (Aluminum Hydroxide):

• Standard adjuvant for human vaccines
• Safe and well-characterized
• May not be optimal for elderly immune responses

• Matrix-M: Saponin-based, enhanced T cell responses
• AS01B: Liposome-containing, strong humoral response
• TLR agonists: Direct immune cell activation

Epitope Selection Strategies

Phospho-Tau Epitopes:

• Mimic pathological phosphorylation states
• Generate antibodies specific to disease-relevant tau
• Examples: pSer396, pSer404, pThr231

• Target pathological tau conformations
• Generate conformation-specific antibodies
• Higher specificity for aggregated tau

• Use B-cell epitopes without T-cell epitopes to avoid autoimmunity
• Link to carrier proteins (e.g., KLH) for T-cell help
• Careful safety monitoring for autoimmune responses

Comparison with Passive Immunotherapy

Combination Approaches

Vaccine + Passive Antibody

Combining active immunization with passive antibodies may provide:

• Initial rapid coverage: Passive antibodies provide immediate protection
• Long-term maintenance: Vaccine generates lasting immunity
• Synergistic effects: Different mechanisms of action
• Challenges: Regulatory complexity, cost

Vaccine + Small Molecule

Combining vaccines with OGA inhibitors or aggregation inhibitors:

• Multiple mechanisms: Vaccine + direct tau clearance
• Potential synergy: Different pathways targeted
• Clinical trials: Such combinations are being planned

Regulatory Considerations

Accelerated Approval Pathway

Tau vaccines may qualify for accelerated approval based on:

• Biomarker endpoints: Tau PET, CSF tau reduction
• Surrogate endpoints: Correlate with clinical benefit
• Unmet need: No approved disease-modifying therapies for tauopathies

Breakthrough Therapy Designation

Programs showing significant efficacy may qualify for:

• Intensive FDA guidance: Rolling review, accelerated approval
• Priority review: Faster regulatory decisions
• Pediatric considerations: Typically adult indications

Future Perspectives

Personalized Vaccination

Emerging approaches include:

• Biomarker-stratified vaccination: Select patients based on tau pathology
• Disease-specific vaccines: Different formulations for AD vs. PSP vs. CBD
• Genetic risk targeting: Focus on high-risk populations

Prevention Trials

Tau vaccines are ideal for prevention settings:

• Asymptomatic individuals: Preclinical AD with biomarker evidence
• Long-lasting protection: Single series provides years of coverage
• Cost-effective: Lower per-patient cost than chronic biologics

Next-Generation Platforms

The field is moving toward:

• Self-amplifying vaccines: Extended antigen production
• Nasal vaccines: Direct CNS immune response
• Gene-gun delivery: Percutaneous delivery to dendritic cells
• Synthetic biology: Engineered antigens for optimal immune response

Global Development Landscape

Multiple global programs are advancing tau vaccines:

Conclusion

Tau vaccines represent a promising yet challenging approach to treating tauopathies. While AADvac1 and ACI-35 have demonstrated the feasibility of generating robust anti-tau antibody responses, translating this into clinical benefit remains elusive. Key learnings include the importance of patient selection, the potential for combination approaches, and the need for novel vaccine technologies that can generate high-affinity, pathology-specific antibodies in elderly patients with age-related immune decline.

References